ANXA1 has been suggested as a biomarker in cholangiocarcinoma [118] and several other cancers including colorectal [119], lung [120], liver [121], pancreatic [122] and breast cancers [123], all of which are extremely heterogeneous and require good biomarkers to inform treatment decisions. Here, ANXA1 is linked to breast cancer.